Dr. Julie Louise Gerberding
Former U.S. CDC Director joins Board of Swiss health technology company: ARTIDIS announces board appointment of Dr. Julie Gerberding, President and CEO of the U.S. Foundation for the National Institutes of Health (FNIH)
September 24, 2024 09:00 ET | Artidis AG
BASEL, Sept. 24, 2024 — ARTIDIS today announced the appointment of Dr. Julie Louise Gerberding to its Board of Directors, effective immediately. Dr. Gerberding is President and CEO of the Foundation...
Artidis-Logo
ARTIDIS Launches Groundbreaking ANGEL Study With Over 2,700 Participants: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient's Bedside
November 02, 2023 08:00 ET | Artidis AG
Houston, Texas, and Basel, Switzerland, November 2nd, 2023 – As Breast Cancer Awareness Month concludes, ARTIDIS announces the launch of its global multicenter clinical trial, ARTIDIS Nanomechanical...
team_members_ajit_400x400
ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors
February 13, 2023 07:15 ET | Artidis AG
ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors Basel, Switzerland, February 13, 2023 – ARTIDIS AG, a clinical stage medical technology company on a mission to shift...
logo_artidis.png
MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment
October 03, 2022 09:05 ET | ARTIDIS AG
HOUSTON and BASEL, Switzerland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- ARTIDIS AG, the developer of the first nanomechanical technology platform for tissue analytics, and The University of Texas MD...
logoArtidis.png
ARTIDIS enters clinical collaboration to investigate nanomechanical profiling as a novel diagnostic and treatment optimization approach in patients with lung cancer
May 04, 2021 01:00 ET | Artidis AG
Basel, Switzerland, May 4, 2021 – ARTIDIS AG, a privately held health-tech company, announces a collaboration with Hospital Clínic de Barcelona and the University of Barcelona to investigate the...
logoArtidis.png
ARTIDIS investigates nanomechanical tissue signature to improve response to radio/immuno-therapy in lung cancer
December 21, 2020 07:30 ET | Artidis AG
Basel, Switzerland, December 21, 2020 – ARTIDIS AG, a privately held health-tech company, investigates the predictive value of nanomechanical tissue signature on outcomes in response to cancer...
logoArtidis.png
ARTIDIS First Prospective Study, "NANO”, Evaluating its Nanotechnology Platform Based on a Novel Nanomechanical Biomarker in Breast Cancer Meets Primary Endpoint
June 22, 2020 07:42 ET | Artidis AG
Basel, Switzerland, June 22, 2020 - ARTIDIS AG, a clinical stage health-tech company, announced today that its proprietary nanotechnology platform for cancer diagnosis has met the primary endpoint in...